BERKELEY HEIGHTS, N.J., Jan. 27, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”) today announced that NASDAQ notified the Company that it has regained compliance with the minimum $50 million market value of listed securities requirement, and further, that it currently complies with all other applicable standards for continued listing on The NASDAQ Global Market.
